Rhode Island Biotechnology Company Wins NIH BioDefense Award; EpiVax Wins SBIR Phase I Grant Totaling $859,773 To Develop Tularemia Vaccine

EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), for developing a genome-derived, epitope-driven tularemia (Francisella tularensis) vaccine.

Back to news